Vestmark Advisory Solutions Inc. Grows Stock Holdings in Amgen Inc. $AMGN

Vestmark Advisory Solutions Inc. boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 52.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,367 shares of the medical research company’s stock after buying an additional 2,525 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Amgen were worth $2,079,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in AMGN. Sequoia Financial Advisors LLC increased its position in Amgen by 2.3% during the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after buying an additional 3,619 shares during the period. Atlantic Union Bankshares Corp boosted its stake in Amgen by 165.0% during the 2nd quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock worth $2,972,000 after purchasing an additional 6,627 shares during the period. Davis Capital Management purchased a new position in Amgen during the 3rd quarter worth $1,841,000. D.A. Davidson & CO. grew its holdings in shares of Amgen by 2.6% during the third quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock worth $68,590,000 after buying an additional 6,222 shares during the last quarter. Finally, Global Wealth Management Investment Advisory Inc. increased its position in Amgen by 56.2% in the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock valued at $3,684,000 after acquiring an additional 4,699 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Price Performance

AMGN stock opened at $382.87 on Wednesday. The firm has a 50 day moving average of $345.41 and a 200-day moving average of $317.87. The company has a market cap of $206.39 billion, a price-to-earnings ratio of 26.91, a PEG ratio of 3.76 and a beta of 0.46. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $385.12.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the previous year, the business earned $5.31 earnings per share. Amgen’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a yield of 2.6%. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Analyst Ratings Changes

AMGN has been the topic of several analyst reports. Citigroup lifted their target price on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Leerink Partners boosted their price objective on shares of Amgen from $305.00 to $355.00 and gave the company an “outperform” rating in a research note on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research report on Thursday, February 5th. Freedom Capital lowered shares of Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 12th. Finally, DZ Bank raised their price objective on shares of Amgen from $335.00 to $364.00 in a research report on Monday, November 10th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $351.76.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Market commentary highlighting recent share-strength and valuation checks has drawn fresh investor attention, supporting momentum off strong YTD and 1‑year returns. Amgen (AMGN) Valuation Check After Recent Share Price Strength And Analyst Fair Value Debate
• Positive Sentiment: Multiple articles argue Amgen is a long-term value/dividend play, reinforcing buy-and-hold interest from income and value-focused investors. Why Amgen (AMGN) is a Top Value Stock for the Long-Term (Zacks)
• Positive Sentiment: Amgen scheduled a presentation at the TD Cowen Health Care Conference (March 2), giving management a platform to update on commercial outlook and the MARITIME trial timetable — a likely near‑term liquidity for investor sentiment. AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
• Neutral Sentiment: Short interest data posted shows zero shares and a short-interest ratio of 0.0 days — this appears to be a reporting anomaly and doesn’t provide a clear signal on bearish positioning.
• Neutral Sentiment: Feature pieces and retrospectives on long‑term returns (Benzinga, MSN) boost narrative momentum but are not new fundamental catalysts. If You Invested $100 In Amgen Stock 15 Years Ago, You Would Have This Much Today
• Negative Sentiment: Barclays initiated coverage with an Equal Weight rating and a $185 price target — a relatively conservative view that could cap upside and prompt some profit‑taking or more cautious positioning among institutional holders. Barclays Begins Amgen (AMGN) Coverage, Notes Balanced Outlook Despite Trial Debate

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.